Translational Research In Glioblastoma Multiforme: Molecular Criteria For Patient Selection
- 11 April 2008
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 4 (2) , 219-228
Abstract
In spite of the dismal outcome of glioblastoma multiforme (GBM), we are in a position to provide a ray of hope to patients and families. Methylation of MGMT in tumor occurs in approximately a third of patients and predicts meaningful response and survival to adjuvant radiotherapy plus temozolomide. Limited access to tumor tissue in some patients could be circumvented by examining MGMT methylation in circulating serum DNA, although this approach needs to be validated. Molecular signatures are also promising prognostic and predictive markers, and clinical trials should be carried out to validate their use in the selection of patients for specific targeted therapies. Gene expression by quantitative PCR of key components of these molecular signatures could pave the way for easy identification of different subgroups of patients. Translational clinical trials are warranted in order to detect the subgroups of patients resistant to radiotherapy who may derive benefit from novel therapies, including antiangiogenic...Keywords
This publication has 42 references indexed in Scilit:
- Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with GlioblastomaClinical Cancer Research, 2007
- Insulin-like growth factor binding protein 2 promotes glioma development and progressionProceedings of the National Academy of Sciences, 2007
- Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage ResponseScience, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancerProceedings of the National Academy of Sciences, 2007
- Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathwayOncogene, 2007
- Compressing drug development timelines in oncology using phase '0' trialsNature Reviews Cancer, 2007
- Scaffolding Protein Grb2-associated Binder 1 Sustains Epidermal Growth Factor-induced Mitogenic and Survival Signaling by Multiple Positive Feedback LoopsJournal of Biological Chemistry, 2006
- Consensus Conference on Cancer Registration of Brain and Central Nervous System TumorsNeuro-Oncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005